MoonLake Immunotherapeutics (HLXA)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation

Ask a question about MoonLake Immunotherapeutics (HLXA)

Company Performance

Current Price

as of Oct 16, 2024

$49.12

P/E Ratio

N/A

Market Cap

$3.09B

Description

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

Metrics

Overview

HQZug, ZG
SectorHealth Technology
IndustryPharmaceuticals: Major
TickerHLXA
Price$49.12+2.33%

Trading Information

Market Cap$3.09B
Float83.74%
Average Daily Volume (1m)439,813
Average Daily Volume (3m)332,626
EPS-$0.90

Company

RevenueN/A
Rev Growth (1yr)N/A
Net Income-$24.27M
Gross MarginN/A
EBITDA MarginN/A
EBITDA-$30.55M

EV$2.26B
EV/RevenueN/A
P/EN/A
P/SN/A
P/B5.93

Documents

Factset Street Account

MoonLake Immunotherapeutics reports Q3 EPS ($0.18) vs FactSet ($0.23) [12 est, ($0.30)-(0.13)] ($36.67, 0.00) (2023-11-14T13:10:16Z)

MoonLake Immunotherapeutics initiated buy at Stifel ($48.56, 0.00) (2023-11-01T20:18:47Z)

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody sonelokimab in active psoriatic arthritis ($51.28, 0.00) (2023-11-05T16:08:56Z)

Follow-up: MoonLake Immunotherapeutics holding call today at 8:00ET to discuss results of phase 2 study of nanobody sonelokimab in active psoriatic arthritis (yesterday) - 8-K ($51.28, 0.00) (2023-11-06T12:59:51Z)